What happens if I overdose Ratchcure?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Proper storage of Ratchcure:
Ratchcure is usually handled and stored by a health care provider. If you are using Ratchcure at home, store Ratchcure as directed by your pharmacist or health care provider. Keep Ratchcure out of the reach of children and away from pets.
Overdose of Ratchcure in details
No information available.
Ratchcure warnings
The following statements take into account the possibility that the constituent drugs of this medicine may be absorbed to a significant degree after topical application. However, the normal use of this medicine is unlikely to present any risk of systemic toxicity unless the application were excessive e.g. more than 200 g per day in adults or proportionately less in children and in patients with compromised renal function.
Following significant systemic absorption polymyxin B sulphate and bacitracin zinc have nephrotoxic potential and polymixin B sulphate has neurotoxic potential.
As with all antibacterial preparations prolonged use may result in the overgrowth of non-susceptible organisms including fungi.
What should I discuss with my healthcare provider before taking Ratchcure?
For all patients taking Ratchcure (ophthalmic):
- If you are allergic to Ratchcure (ophthalmic); any part of Ratchcure (ophthalmic); or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had.
- If you or a family member have ever had any of these health problems: Blood or bone marrow problems like aplastic anemia.
- If Ratchcure (ophthalmic) has caused anemia, low platelet count, or low white blood cell count before.
- If you are taking any drugs that can stop your bone marrow from making some of the cells that your body needs. There are many drugs that can do this. Ask your doctor or pharmacist if you are not sure.
- If you are pregnant.
- If you are breast-feeding or plan to breast-feed.
Children:
- If your child is a newborn. Some brands of Ratchcure (ophthalmic) are not for use in newborns.
This is not a list of all drugs or health problems that interact with Ratchcure (ophthalmic).
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Ratchcure (ophthalmic) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
Ratchcure precautions
Concerns related to adverse effects:
• Blood dyscrasias: [US Boxed Warning]: Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) have occurred after both short-term and prolonged therapy; do not use for minor infections or when less potentially toxic agents are effective. Monitor CBC frequently in all patients; discontinue if evidence of myelosuppression. Irreversible bone marrow suppression may occur weeks or months after therapy. Avoid prolonged or repeated courses of treatment.
• Gray syndrome: Characterized by cyanosis, abdominal distention, vasomotor collapse (often with irregular respiration), and death. Reaction appears to be associated with serum levels ≥50 mcg/mL (Powell 1982).
• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.
Disease-related concerns:
• Hepatic impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.
• Renal impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Special populations:
• Glucose 6-phosphate dehydrogenase deficiency: Use with caution in patients with glucose 6-phosphate dehydrogenase deficiency.
• Neonates: Use in premature and full-term neonates and infants has resulted in “gray syndrome" characterized by cyanosis, abdominal distention (with or without emesis), vasomotor collapse (often with irregular respiration), and death; progression of symptoms is rapid; prompt termination of therapy required. Reaction may result from drug accumulation caused by immature hepatic or renal function in neonates and infants.
References
- DailyMed. "CHLORAMPHENICOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DrugBank. "chloramphenicol". http://www.drugbank.ca/drugs/DB00446 (accessed September 17, 2018).
- MeSH. "Protein Synthesis Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
